Celecoxib (GMP)

Celecoxib (GMP) is Celecoxib (HY-14398) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.

Product Specifications

CAS Number

[169590-42-5]

Product Name Alternative

SC 58635 (GMP)

UNSPSC

12352005

Hazard Statement

H360-H373-H401-H410

Target

COX

Type

GMP Small Molecules

Related Pathways

Immunology/Inflammation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/celecoxib-gmp.html

Solubility

10 mM in DMSO

Smiles

CC1=CC=C(C=C1)C2=CC(C(F)(F)F)=NN2C3=CC=C(C=C3)S(=O)(N)=O

Molecular Formula

C17H14F3N3O2S

Molecular Weight

381.37

Precautions

P260-P273-P280-P391-P405-P501

References & Citations

[1]Pobbati AV, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10 (8) :3622-3635.|[2]Hou XL, et al. Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone. Neural Regen Res. 2015 Nov;10 (11) :1836-40.|[3]Suri A, et al. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer. Oncotarget. 2016 Apr 8.|[4]Liu DB, et al. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin. 2012 May;33 (5) :682-90.|[5]Penning TD, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5- (4-methylphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib) . J Med Chem. 1997|[6]Liu C, et al. Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. Sci Rep. 2018 Mar 7;8 (1) :4108.|[7]Chen Y, Wu B, Lin J, et al. High-Resolution Dissection of Chemical Reprogramming from Mouse Embryonic Fibroblasts into Fibrocartilaginous Cells. Stem Cell Reports. 2020;14 (3) :478-492. |[8]Kaushik K, Das A. Cycloxygenase-2 inhibition potentiates trans-differentiation of Wharton's jelly-mesenchymal stromal cells into endothelial cells: Transplantation enhances neovascularization-mediated wound repair. Cytotherapy. 2019;21 (2) :260-273.|[9]Vieceli Dalla Sega F, Fortini F, Cimaglia P, et al. COX-2 Is Downregulated in Human Stenotic Aortic Valves and Its Inhibition Promotes Dystrophic Calcification. Int J Mol Sci. 2020;21 (23) :8917. Published 2020 Nov 24. doi:10.3390/ijms21238917